How Should Healthy Volunteers Evaluate Paid Phase I Clinical Trials?

How much do paid clinical trials usually pay?

Published healthy-volunteer data put the median payment per Phase I trial at US$3,070, but the useful number is not the median. It is the payment attached to this study's visits, confinement, procedures, travel, and withdrawal terms.

A three-year longitudinal study of 131 healthy volunteers reported trial payments from US$150 to US$13,000. Most trials in that sample, 65.1%, offered less than US$4,000, while fewer than 2% offered more than US$10,000. The same research found that participants commonly screened for three trials yearly, enrolled in one or two, and earned roughly US$4,000 annually; it was exceedingly rare to earn more than US$20,000 in a year. Read the full compensation context in the Phase I compensation study.

Use the headline-versus-terms check. A large number can reflect a longer study or confinement requirement rather than a higher level of risk. It may also include separate pieces: payment for time and inconvenience, reimbursement for travel or other expenses, and a completion-related amount. Do not merge those categories in your head. Ask the site to separate them.

The U.S. Office for Human Research Protections says payment is common and generally acceptable, but an institutional review board, or IRB, must consider whether it could improperly influence voluntary consent. The payment amount and purpose should be justified to the IRB and clearly described in the consent materials. That is a protection, not a shortcut: you still need to decide whether the terms work for you.

Are paid clinical trials safe for healthy volunteers?

Paid Phase I trials carry real risks for healthy volunteers, even though published reviews found low rates of severe harm; payment does not remove those risks or create a direct medical benefit.

A meta-analysis of 394 non-oncology Phase I studies at three dedicated sites included 11,028 healthy people who received study drug. Of reported adverse events, 84.6% were mild and 1.0% were severe; 34 serious adverse events occurred, or 0.31%, with no deaths or life-threatening events in that dataset. Headache, drowsiness, and diarrhea were the most commonly reported events. The BMJ/PubMed analysis also cautioned against extending those results to all Phase I studies, especially biological agents.

A separate systematic review of 475 published Phase I trials involving 27,185 healthy participants concluded that Phase I research causes mild and moderate harms while showing low risks of severe harm in the published studies reviewed. It also makes the key distinction: healthy volunteers generally receive no direct medical benefit. The payment is compensation for participating. It is not treatment, and it is not an insurance policy against a bad outcome.

Run a risk-and-routine check before signing. Ask, “What drug risks and procedure risks are reasonably foreseeable?” Then ask, “Which procedures are experimental, how long will each visit take, and what would make the investigator end my participation?” This is the same practical habit behind asking specific health questions before a decision, such as in this guide to what to discuss before taking supplements for hair shedding.

The HHS consent checklist requires disclosure of the study purpose, expected duration, procedures, experimental procedures, and reasonably foreseeable risks or discomforts. For research involving more than minimal risk, it also requires information about whether compensation and medical treatment are available for a research-related injury, or where to get more information. Ask for the contact for research questions, participant-rights questions, and injury questions. Three contacts, three different jobs.

Do I get paid if I leave a clinical trial early?

You have the right to leave a clinical trial at any time, but whether and how much you are paid after leaving depends on the payment terms stated in the consent form.

HHS regulations require consent to say that participation is voluntary and that a participant may discontinue at any time without penalty or loss of benefits they are otherwise entitled to. OHRP recommends prorating payment over the time spent in a study instead of delaying it all until completion, because withholding all payment can improperly influence the choice to withdraw. The consent form should plainly say when you receive partial payment or no payment if you withdraw or are removed.

Do not settle for “you can withdraw whenever you want.” Use the stronger version: “If I withdraw after this visit, what payment is due, what safety follow-up is recommended, and what information already collected remains in the study?” OHRP explains that after full withdrawal, investigators must stop new research interactions, interventions, and collection of additional identifiable private information. In FDA-regulated trials, data collected before withdrawal generally remain in the trial database and are included in analysis; consent should explain that point.

There is also a safety layer. Leaving may involve orderly termination procedures, especially when follow-up is needed. Ask what happens next rather than simply skipping contact: “What is the safest way to end participation, and what follow-up do you recommend?” OHRP's withdrawal guidance says the process should explain withdrawal consequences and procedures for ending participation safely.

Use the Consent-Form Drill Before You Sign

Run this drill with the consent form open. Your job is not to sound agreeable. Your job is to reduce ambiguity before it costs time, money, or peace of mind.

1. Circle the schedule. Count screening, dosing, confinement, and follow-up visits. Ask: “Which parts are required for payment, and which are recommended for safety?”
2. Mark every procedure. Ask: “Which procedures are experimental, and what discomforts should I expect from each?”
3. Find the injury language. Ask: “If a research-related injury occurs, what compensation or medical treatment is available, and who gives me that information?”
4. Trace the payment path. Ask: “What is paid per completed visit, what is reimbursed separately, and what changes if I withdraw or you remove me?”
5. Save the contacts. Keep the numbers for study questions, participant rights, and research-related injury before the first procedure.

The point is simple. A good consent conversation lowers cognitive load because it converts a vague offer into a schedule of obligations, risks, and rights. If a question gets a fuzzy answer, ask for the relevant consent-form language. Then decide.